Yubo International Biotech Ltd (YBGJ)
↓ Download CSV- Sector Manufacturing
- Incorporated NY
- Fiscal year ends Dec 31
In fiscal 2025, Yubo International Biotech Ltd reported revenue of $12.4K, up 256.0% from the prior year. The company ran a net loss, with a net margin of -8736.7% and a gross margin of 66.1%. It held $847.1K in total assets against $2.79M in total liabilities.
Key ratios (FY2025)
66.1%
Gross margin
-9614.6%
Operating margin
-8736.7%
Net margin
+256.0%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.4K | $3.5K | $604.7K | $104.3K | $1.24M | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | $4.2K | $822 | $185.5K | $51.6K | $423.7K | $114.3K | — | — | — | — |
| Gross Profit | $8.2K | $2.6K | $419.2K | $52.7K | $820.6K | $1.24M | — | — | — | — |
| Operating Income | -$1.19M | -$1.77M | -$1.19M | -$1.21M | -$1.54M | -$711.8K | -$48.0K | -$58.0K | -$149.0K | -$63.0K |
| Net Income | -$1.08M | -$1.78M | -$1.20M | -$1.20M | -$1.54M | -$711.8K | -$148.0K | -$144.0K | -$224.0K | -$130.0K |
| EPS (Diluted) | $-0.01 | $-0.02 | $-0.10 | — | — | — | — | — | — | — |
| Total Assets | $847.1K | $1.53M | $1.67M | $2.35M | $4.59M | $2.44M | $4.0K | — | — | — |
| Total Liabilities | $2.79M | $4.83M | $3.51M | $2.91M | $4.72M | $1.28M | — | — | — | — |
| Shareholders' Equity | -$1.95M | -$3.42M | -$1.84M | -$565.4K | -$131.2K | $1.17M | $488.7K | -$1.52M | -$1.37M | -$1.26M |
| Cash & Equivalents | $8.1K | $7.0K | $6.4K | $18.2K | $27.5K | $1.38M | $1.3K | $2.0K | $1.0K | $11.0K |
| Operating Cash Flow | -$842.8K | -$1.34M | -$739.0K | -$601.0K | -$1.02M | $101.1K | -$32.0K | -$55.0K | -$55.0K | -$56.0K |
| Capital Expenditures | — | — | — | $0 | $564.7K | $42.6K | — | — | — | — |
| Shares Outstanding | 139.64M | 119.82M | 11.98M | — | — | 1.18M | 1.18M | — | — | — |